Valence ロゴ
人気
ログイン

ウォッチリストに追加

Prelude Therapeutics

NasdaqGS: PRLD · リアルタイム株価 · USD
5.75
+0.12 (2.13%)
終値時点： Aug 18, 2026, 3:59 PM

Prelude Therapeutics (PRLD) Stock Price, Analysis & Data

2.13%
買気配4.11
時価総額458.87M
売上高（TTM）22.42M
純利益（TTM）-60.49M
ベータ0.94
EPS（TTM）-0.74
PER（TTM）n/a
予想PER-7.67
PBR（TTM）4.43
PSR（TTM）20.42
Earnings DateNov 11, 2026
売気配7.1
出来高267,747
平均出来高（20日）421,724
始値5.62
前日終値5.63
当日レンジ5.49 - 5.78
52週レンジ0.85 - 5.91
アナリストStrong Buy
目標株価8 (39.13%)
配当n/a
権利落ち日n/a

PRLDについて

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated ca...

[続きを読む]
業種 Biotechnology
セクター Healthcare
IPO日 Sep 25, 2020
従業員数 79
上場取引所 NasdaqGS
ティッカー PRLD
ウェブサイト https://preludetx.com
企業情報の全文

業績

2025年のPrelude Therapeuticsの売上高は12.14Mで、前年の7Mから73.43%の増加でした。 利益は-99.5Mで、-21.76%の減少でした。

財務諸表

アナリスト予想

3件のアナリスト評価によると、PRLD株の平均レーティングは「Strong Buy」です。12か月後の目標株価は8で、直近株価から39.13%の上昇余地となります。

株価予想

決算サプライズ

Prelude TherapeuticsはAug 11, 2026に四半期決算を発表しました：
  • 売上高は $4.58M で、予想を下回りました $0, うち Infinity% の前年比増加にあたります.
  • EPSは -0.14 で、予想を上回りました 0.04, うち 65.85% の前年比増加にあたります.

    • 次回決算発表

    Prelude Therapeuticsの決算発表予定日は Nov 11, 2026, 寄り付き前の予定です。
    アナリストの売上高予想は ... アップグレード
    news image

    6日前 · Stocktwits

    Sellas’ Experimental Drug SLS009 Appears To Be Leading The CDK9 Race, Says Alliance Global – Analyst Sees About 200% Upside Potential

    Alliance Global analyst James Molloy said SLS009, which is being developed for acute myeloid leukemia, could potentially be used to treat additional cancers.

    news image

    2週間前 · Zacks

    Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?

    The consensus price target hints at a 58.4% upside potential for Prelude Therapeutics (PRLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earni...

    news image

    1か月前 · Zacks

    Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why

    Prelude Therapeutics (PRLD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

    news image

    2か月前 · Insider Monkey

    Goldman Sachs Initiates Coverage of Prelude Therapeutics (PRLD)

    Prelude Therapeutics Incorporated (NASDAQ:PRLD) is one of the 10 Most Volatile Penny Stocks to Buy Now. On May 15, 2026, Goldman Sachs analyst Corinne Johnson initiated coverage of Prelude Therapeutic...

    news image

    3か月前 · Simply Wall St.

    Earnings Beat: Prelude Therapeutics Incorporated (NASDAQ:PRLD) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

    Last week, you might have seen that Prelude Therapeutics Incorporated ( NASDAQ:PRLD ) released its quarterly result to...

    2ページ中1ページ